Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2049)	12/13/2007 9:50:19 AM
From: Jibacoa	Respond to of 3722

NBIX is down 44.8% after announcing that it received a letter from the FDA requesting additional preclinical data before it would approve the NDA for indiplon 5 & 10 mg capsules for the treatment of insomnia. bigcharts.marketwatch.com The requirements are as follows: An objective/subjective clinical trial in the elderly. A safety study assessing the rates of adverse events occurring with indiplon when compared to a marketed product. A preclinical study to evaluate indiplon administration during the third trimester of pregnancy. Bernard

To: Jibacoa who wrote (2049)	2/27/2008 11:46:04 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

MEDX is doing better after releasing its 4thQ results yesterday. The stock is up 7.59% on volume of 1,405,615 > half its ADV bigcharts.marketwatch.com Revenues were significantly better at $20.5M vs. $11.3M. an improvement of 81%.The loss was cut some to $0.31/shr from $0/36/shr in 2006 But the EL for 2008 is higher, around $1.45/shr vs. the $1.20 loss in 2007 MEDX sold recently 2.5M shrs of Genmab for approximately $151.8M & still owns approximately 5.1% of Genmab. The stock remains on a long term DT. Its March 2000 H was $103.<g> bigcharts.marketwatch.com Bernard